ZELLUNA ASA (ZLNA.OL) Stock Price & Overview
OSL:ZLNA • NO0013524942
The current stock price of ZLNA.OL is 15.596 NOK. Today ZLNA.OL is down by -2.52%. In the past month the price increased by 3.97%. In the past year, price increased by 623.71%.
ZLNA.OL Key Statistics
- Market Cap
- 409.707M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -38.70
- Dividend Yield
- N/A
ZLNA.OL Stock Performance
ZLNA.OL Stock Chart
ZLNA.OL Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ZLNA.OL. When comparing the yearly performance of all stocks, ZLNA.OL is one of the better performing stocks in the market, outperforming 99.44% of all stocks.
ZLNA.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ZLNA.OL. No worries on liquidiy or solvency for ZLNA.OL as it has an excellent financial health rating, but there are worries on the profitability.
ZLNA.OL Earnings
ZLNA.OL Forecast & Estimates
9 analysts have analysed ZLNA.OL and the average price target is 25.5 NOK. This implies a price increase of 63.5% is expected in the next year compared to the current price of 15.596.
ZLNA.OL Groups
Sector & Classification
ZLNA.OL Financial Highlights
Over the last trailing twelve months ZLNA.OL reported a non-GAAP Earnings per Share(EPS) of -38.7. The EPS increased by 10.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -269.09% | ||
| ROE | -337.63% | ||
| Debt/Equity | 0 |
ZLNA.OL Ownership
ZLNA.OL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 25.78 | 38.504B | ||
| 1AE | ARGENX SE | 25.73 | 38.43B | ||
| 22UA | BIONTECH SE-ADR | N/A | 20.836B | ||
| 2X1 | ABIVAX SA | N/A | 7.449B | ||
| ABVX | ABIVAX SA | N/A | 7.433B | ||
| GXE | GALAPAGOS NV | N/A | 1.86B | ||
| GLPG | GALAPAGOS NV | N/A | 1.856B | ||
| NANO | NANOBIOTIX | N/A | 1.386B | ||
| 6IV | INVENTIVA SA | N/A | 1.094B | ||
| IVA | INVENTIVA SA | N/A | 1.071B | ||
| PHIL | PHILOGEN SPA | 17.21 | 628.66M | ||
| GNFT | GENFIT | 835.29 | 426.025M | ||
| XUP | GENFIT | N/A | 425.025M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Oslo Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About ZLNA.OL
Company Profile
Zelluna ASA is a biotechnology company focused on developing innovative and cost-efficient therapies for advanced solid cancers. The company is headquartered in Oslo, Oslo. The company went IPO on 2019-06-03. The firm develops cell therapies for the treatment of cancer patients. Zelluna ASA deals with eliminate solid cancers by unleashing thel elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies. The firm provides benefit to patients, their families and all those around them, by developing therapies that bring together TCR guidance with the effector functions of allogeneic NK cells (TCR-NK) deploying a mechanism of action that has the potential to be both safe and potent. Zelluna ASA operates worldwide.
Company Info
ZELLUNA ASA
Ullernchausseen 64
Oslo OSLO NO
Employees: 26
Phone: 4741380080
ZELLUNA ASA / ZLNA.OL FAQ
What does ZELLUNA ASA do?
Zelluna ASA is a biotechnology company focused on developing innovative and cost-efficient therapies for advanced solid cancers. The company is headquartered in Oslo, Oslo. The company went IPO on 2019-06-03. The firm develops cell therapies for the treatment of cancer patients. Zelluna ASA deals with eliminate solid cancers by unleashing thel elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies. The firm provides benefit to patients, their families and all those around them, by developing therapies that bring together TCR guidance with the effector functions of allogeneic NK cells (TCR-NK) deploying a mechanism of action that has the potential to be both safe and potent. Zelluna ASA operates worldwide.
Can you provide the latest stock price for ZELLUNA ASA?
The current stock price of ZLNA.OL is 15.596 NOK. The price decreased by -2.52% in the last trading session.
Does ZLNA stock pay dividends?
ZLNA.OL does not pay a dividend.
What is the ChartMill technical and fundamental rating of ZLNA stock?
ZLNA.OL has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of ZELLUNA ASA (ZLNA.OL)?
ZELLUNA ASA (ZLNA.OL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-38.7).
What is the employee count for ZLNA stock?
ZELLUNA ASA (ZLNA.OL) currently has 26 employees.
Who owns ZELLUNA ASA?
You can find the ownership structure of ZELLUNA ASA (ZLNA.OL) on the Ownership tab.